PharMS-supported MRwarfarin
…per 10,000 MR cases (95% CI: 0.13–3.9).Conclusion and Relevance PharMS-supported MR in 2025 achieved high timeliness, improved efficiency, and enha…
Entity family
Programmes, procedures, policies, and other actions being evaluated. Examples include screening, surgery, public-health programmes.
This intervention is selected. Its supporting articles are shown below.
…per 10,000 MR cases (95% CI: 0.13–3.9).Conclusion and Relevance PharMS-supported MR in 2025 achieved high timeliness, improved efficiency, and enha…